1. Academic Validation
  2. Therapeutic effects of orexin-A in sepsis-associated encephalopathy in mice

Therapeutic effects of orexin-A in sepsis-associated encephalopathy in mice

  • J Neuroinflammation. 2024 May 17;21(1):131. doi: 10.1186/s12974-024-03111-w.
Jing Guo 1 Zhuo Kong 2 Sha Yang 1 Jingjing Da 3 Liangzhao Chu 4 Guoqiang Han 2 Jian Liu 5 Ying Tan 6 Jiqin Zhang 7
Affiliations

Affiliations

  • 1 GuiZhou University Medical College, Guiyang, 550025, Guizhou Province, China.
  • 2 Department of Neurosurgery, Guizhou Provincial People's Hospital, Guiyang, China.
  • 3 Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, China.
  • 4 Department of Neurosurgery, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • 5 Department of Neurosurgery, Guizhou Provincial People's Hospital, Guiyang, China. liujian@gz5055.com.
  • 6 Department of Neurosurgery, Guizhou Provincial People's Hospital, Guiyang, China. tanying@gz5055.com.
  • 7 Department of Anesthesiology, Guizhou Provincial People's Hospital, Guiyang, China. zhangjiqin@gz5055.com.
Abstract

Background: Sepsis-associated encephalopathy (SAE) causes acute and long-term cognitive deficits. However, information on the prevention and treatment of cognitive dysfunction after sepsis is limited. The neuropeptide orexin-A (OXA) has been shown to play a protective role against neurological diseases by modulating the inflammatory response through the activation of OXR1 and OXR2 receptors. However, the role of OXA in mediating the neuroprotective effects of SAE has not yet been reported.

Methods: A mouse model of SAE was induced using cecal ligation perforation (CLP) and treated via intranasal administration of exogenous OXA after surgery. Mouse survival, in addition to cognitive and anxiety behaviors, were assessed. Changes in neurons, cerebral edema, blood-brain barrier (BBB) permeability, and brain ultrastructure were monitored. Levels of pro-inflammatory factors (IL-1β, TNF-α) and microglial activation were also measured. The underlying molecular mechanisms were investigated by proteomics analysis and western blotting.

Results: Intranasal OXA treatment reduced mortality, ameliorated cognitive and emotional deficits, and attenuated cerebral edema, BBB disruption, and ultrastructural brain damage in mice. In addition, OXA significantly reduced the expression of the pro-inflammatory factors IL-1β and TNF-α, and inhibited microglial activation. In addition, OXA downregulated the expression of the Rras and Ras proteins, and reduced the phosphorylation of P-38 and JNK, thus inhibiting activation of the MAPK pathway. JNJ-10,397,049 (an OXR2 blocker) reversed the effect of OXA, whereas SB-334,867 (an OXR1 blocker) did not.

Conclusion: This study demonstrated that the intranasal administration of moderate amounts of OXA protects the BBB and inhibits the activation of the OXR2/Ras/MAPK pathway to attenuate the outcome of SAE, suggesting that OXA may be a promising therapeutic approach for the management of SAE.

Keywords

Cognitive dysfunction; Inflammation; Orexin receptors; Orexin-A; Sepsis-associated encephalopathy.

Figures
Products